Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care

Katherine Riccione, Carter M. Suryadevara, David Snyder, Xiuyu Cui, John H. Sampson, Luis Sanchez-Perez

Research output: Contribution to journalArticlepeer-review

18 Scopus citations


Adoptive T cell immunotherapy offers a promising strategy for specifically targeting and eliminating malignant gliomas. T cells can be engineered ex vivo to express chimeric antigen receptors specific for glioma antigens (CAR T cells). The expansion and function of adoptively transferred CAR T cells can be potentiated by the lymphodepletive and tumoricidal effects of standard of care chemotherapy and radiotherapy. We describe a method for generating CAR T cells targeting EGFRvIII, a glioma-specific antigen, and evaluating their efficacy when combined with a murine model of glioblastoma standard of care. T cells are engineered by transduction with a retroviral vector containing the anti-EGFRvIII CAR gene. Tumor-bearing animals are subjected to host conditioning by a course of temozolomide and whole brain irradiation at dose regimens designed to model clinical standard of care. CAR T cells are then delivered intravenously to primed hosts. This method can be used to evaluate the antitumor efficacy of CAR T cells in the context of standard of care.

Original languageEnglish
Article numbere52397
JournalJournal of Visualized Experiments
Issue number96
StatePublished - 16 Feb 2015
Externally publishedYes


  • Adoptive transfer
  • Chimeric antigen receptor
  • Glioblastoma
  • Immunology
  • Issue 96
  • Radiotherapy
  • Temozolomide
  • Tumor immunotherapy


Dive into the research topics of 'Generation of CAR T cells for adoptive therapy in the context of glioblastoma standard of care'. Together they form a unique fingerprint.

Cite this